Home > Insider Trading > Filing (0001209191-21-042082)

Filing Details

Accession Number:: 0001209191-21-042082
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-21 16:54:26
Reporting Period:: 2021-06-16

Accepted Time:: 2021-06-21 16:54:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724521	Arcus Biosciences Inc.	RCUS	Pharmaceutical Preparations (2834)	473898435

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1836662	C. Carolyn Tang	C/O Arcus Biosciences, Inc. 3928 Point Eden Way Hayward CA 94545	General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-06-16	1,257	$24.13	17,020	No	4	S	Direct
Common Stock	Disposition	2021-06-16	52	$24.77	16,968	No	4	S	Direct
Common Stock	Disposition	2021-06-17	1,606	$23.68	15,362	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Includes 2,679 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.